Cargando…

The failed HIV Merck vaccine study: a step back or a launching point for future vaccine development?

The world of human immunodeficiency virus (HIV) vaccines has suffered a baffling setback. The first trial of a vaccine designed to elicit strong cellular immunity has shown no protection against infection. More alarmingly, the vaccine appeared to increase the rate of HIV infection in individuals wit...

Descripción completa

Detalles Bibliográficos
Autor principal: Sekaly, Rafick-Pierre
Formato: Texto
Lenguaje:English
Publicado: The Rockefeller University Press 2008
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2234358/
https://www.ncbi.nlm.nih.gov/pubmed/18195078
http://dx.doi.org/10.1084/jem.20072681
_version_ 1782150348935266304
author Sekaly, Rafick-Pierre
author_facet Sekaly, Rafick-Pierre
author_sort Sekaly, Rafick-Pierre
collection PubMed
description The world of human immunodeficiency virus (HIV) vaccines has suffered a baffling setback. The first trial of a vaccine designed to elicit strong cellular immunity has shown no protection against infection. More alarmingly, the vaccine appeared to increase the rate of HIV infection in individuals with prior immunity against the adenovirus vector used in the vaccine. A new study in this issue suggests that a different vaccine approach—using a DNA prime/poxvirus boost strategy—induces polyfunctional immune responses to an HIV immunogen. The disappointing results of the recent vaccine trial suggest that a more thorough assessment of vaccine-induced immune responses is urgently needed, and that more emphasis should be placed on primate models before efficacy trials are undertaken.
format Text
id pubmed-2234358
institution National Center for Biotechnology Information
language English
publishDate 2008
publisher The Rockefeller University Press
record_format MEDLINE/PubMed
spelling pubmed-22343582008-07-21 The failed HIV Merck vaccine study: a step back or a launching point for future vaccine development? Sekaly, Rafick-Pierre J Exp Med Commentary The world of human immunodeficiency virus (HIV) vaccines has suffered a baffling setback. The first trial of a vaccine designed to elicit strong cellular immunity has shown no protection against infection. More alarmingly, the vaccine appeared to increase the rate of HIV infection in individuals with prior immunity against the adenovirus vector used in the vaccine. A new study in this issue suggests that a different vaccine approach—using a DNA prime/poxvirus boost strategy—induces polyfunctional immune responses to an HIV immunogen. The disappointing results of the recent vaccine trial suggest that a more thorough assessment of vaccine-induced immune responses is urgently needed, and that more emphasis should be placed on primate models before efficacy trials are undertaken. The Rockefeller University Press 2008-01-21 /pmc/articles/PMC2234358/ /pubmed/18195078 http://dx.doi.org/10.1084/jem.20072681 Text en Copyright © 2008, The Rockefeller University Press This article is distributed under the terms of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months after the publication date (see http://www.rupress.org/terms). After six months it is available under a Creative Commons License (Attribution–Noncommercial–Share Alike 4.0 Unported license, as described at http://creativecommons.org/licenses/by-nc-sa/4.0/).
spellingShingle Commentary
Sekaly, Rafick-Pierre
The failed HIV Merck vaccine study: a step back or a launching point for future vaccine development?
title The failed HIV Merck vaccine study: a step back or a launching point for future vaccine development?
title_full The failed HIV Merck vaccine study: a step back or a launching point for future vaccine development?
title_fullStr The failed HIV Merck vaccine study: a step back or a launching point for future vaccine development?
title_full_unstemmed The failed HIV Merck vaccine study: a step back or a launching point for future vaccine development?
title_short The failed HIV Merck vaccine study: a step back or a launching point for future vaccine development?
title_sort failed hiv merck vaccine study: a step back or a launching point for future vaccine development?
topic Commentary
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2234358/
https://www.ncbi.nlm.nih.gov/pubmed/18195078
http://dx.doi.org/10.1084/jem.20072681
work_keys_str_mv AT sekalyrafickpierre thefailedhivmerckvaccinestudyastepbackoralaunchingpointforfuturevaccinedevelopment
AT sekalyrafickpierre failedhivmerckvaccinestudyastepbackoralaunchingpointforfuturevaccinedevelopment